Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
5(71.4%)
Phase 4
2(28.6%)
7Total
N/A(5)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06920953Not Yet Recruiting

Participant Satisfaction and Quality of Life With Catheter Washouts in Adults Living With Long-Term Catheters and Currently Using Uro-Tainer® Polihexanide 0.02%

Role: lead

NCT04902651Not ApplicableTerminated

HM242-Gel vs Comparator

Role: lead

NCT04902612Not ApplicableUnknown

HM242-Solution vs Comparator

Role: lead

NCT04192123Not ApplicableCompleted

Open-Label Test of the HM242 Medical Devices to Evaluate Safety and Local Tolerability

Role: lead

NCT01534858Not ApplicableCompleted

A Prospective, Descriptive Cohort Study With Prontosan® Wound Gel X in Partial and Full Thickness Burns Requiring Split Thickness Skin Grafts

Role: lead

NCT02157415Not ApplicableTerminated

Prospective Cohort Study on Tolerability & Safety of Uro-Tainer® Polihexanide 0.02%

Role: lead

NCT01153633Phase 4Completed

Trial on the Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel

Role: lead

NCT01153620Phase 4Completed

The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds

Role: lead

All 8 trials loaded